Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Searle_Pharmaceuticals
|
| gptkbp:activities |
dopamine receptor antagonist
serotonin receptor antagonist |
| gptkbp:approves |
gptkb:1996
gptkb:FDA |
| gptkbp:brand |
gptkb:Zyprexa
|
| gptkbp:category |
gptkb:C
|
| gptkbp:class |
atypical antipsychotic
|
| gptkbp:clinical_trial |
depression treatment
anxiety treatment bipolar disorder treatment schizophrenia treatment post-traumatic stress disorder treatment |
| gptkbp:contraindication |
severe liver impairment
hypersensitivity to olanzapine |
| gptkbp:developed_by |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:form |
orally disintegrating tablet
long-acting injection |
| gptkbp:formulation |
gptkb:tablet
injectable orally disintegrating tablet long-acting injection |
| https://www.w3.org/2000/01/rdf-schema#label |
Olanzapine
|
| gptkbp:ingredients |
C17 H20 N4 S
|
| gptkbp:interacts_with |
gptkb:beer
antidepressants CNS depressants antihypertensives anticonvulsants |
| gptkbp:is_available_on |
gptkb:tablet
injectable solution |
| gptkbp:is_monitored_by |
gptkb:weight
lipid profile blood glucose |
| gptkbp:is_used_for |
treatment of schizophrenia
treatment of bipolar disorder |
| gptkbp:lifespan |
21 hours
|
| gptkbp:manager |
oral
intramuscular |
| gptkbp:metabolism |
liver
|
| gptkbp:side_effect |
metabolic syndrome
drowsiness constipation dry mouth weight gain sedation increased appetite extrapyramidal symptoms neuroleptic malignant syndrome tardive dyskinesia |
| gptkbp:traded_on |
gptkb:Zyprexa_Relprevv
gptkb:Zyprexa_Zydis |
| gptkbp:type_of |
132539-06-1
|